125 related articles for article (PubMed ID: 28733196)
21. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Wang L; Kumar S; Fridley BL; Kalari KR; Moon I; Pelleymounter LL; Hildebrandt MA; Batzler A; Eckloff BW; Wieben ED; Greipp PR
Clin Cancer Res; 2008 Jun; 14(11):3503-13. PubMed ID: 18519783
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
23. [Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma].
Espinoza Zelada M; Befferman Cordova N; Ocqueteau Tachini M; Ramírez Villanueva P; Galleguillos M M; Sarmiento Maldonado M
Medwave; 2015 Mar; 15(2):e6098. PubMed ID: 25831273
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
Jimenez-Zepeda VH; Duggan P; Neri P; Tay J; Bahlis NJ
Ann Hematol; 2017 Mar; 96(3):431-439. PubMed ID: 28074255
[TBL] [Abstract][Full Text] [Related]
27. Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.
Chee A; Low MS; Vilcassim S; Gregory GP; Gilbertson M; Ratnasingam S; Grigoriadis G; Fedele PL
Br J Haematol; 2018 Sep; 182(5):739-741. PubMed ID: 28857117
[No Abstract] [Full Text] [Related]
28.
Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
30. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
31. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T; Terpos E; Eleutherakis-Papaiakovou E; Kalapanida D; Gavriatopoulou M; Migkou M; Liacos CI; Tasidou A; Matsouka C; Mparmparousi D; Dimopoulos MA; Kastritis E
Br J Haematol; 2016 Jan; 172(1):44-7. PubMed ID: 26564000
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
34. Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Sood N; Hamide A; Dubashi B; Nisha Y; Mathaiyan J; Munirajan AK; Ganesn P; Kayal S
Asian Pac J Cancer Prev; 2024 Mar; 25(3):829-837. PubMed ID: 38546066
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
37. Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
Barrio S; Stühmer T; Da-Viá M; Barrio-Garcia C; Lehners N; Besse A; Cuenca I; Garitano-Trojaola A; Fink S; Leich E; Chatterjee M; Driessen C; Martinez-Lopez J; Rosenwald A; Beckmann R; Bargou RC; Braggio E; Stewart AK; Raab MS; Einsele H; Kortüm KM
Leukemia; 2019 Feb; 33(2):447-456. PubMed ID: 30026573
[TBL] [Abstract][Full Text] [Related]
38. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D; Luczak M; Wrobel T; Usnarska-Zubkiewicz L; Brzezniakiewicz K; Jamroziak K; Giannopoulos K; Przybylowicz-Chalecka A; Ratajczak B; Czerwinska-Rybak J; Nowicki A; Joks M; Czechowska E; Zawartko M; Szczepaniak T; Grzasko N; Morawska M; Bochenek M; Kubicki T; Morawska M; Tusznio K; Jakubowiak A; Komarnicki MA
Oncotarget; 2016 Aug; 7(35):56726-56736. PubMed ID: 27527861
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
